Amgen's Nplate meets both primary endpoints
This article was originally published in Scrip
Executive Summary
Nplate, Amgen’s fusion protein analog of thrombopoietin, achieved its primary endpoints of reducing the incidence of treatment failure and reducing the incidence of splenectomy in adults with chronic immune thrombocytopenia (ITP), according to a study published in the 10 November of the New England Journal of Medicine. The drug is already approved for chronic ITP, but this was the first study that compared a variety of ITP treatments including standard-of-care for ITP.